Meta-analysis: Levamisole improves the immune response to hepatitis B vaccine in dialysis patients

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 6, 2010, Pages 756-762

  Fabrizi, F ^a,b   Dixit, V ^b   Messa, P ^a   Martin, P ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; LEVAMISOLE;

ABDOMINAL PAIN; ADJUVANT THERAPY; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; DERMATITIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEMODIALYSIS PATIENT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LEUKOPENIA; META ANALYSIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RISK ASSESSMENT; SEROLOGY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS AS TOPIC; DIALYSIS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; KIDNEY FAILURE, CHRONIC; LEVAMISOLE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77955756082     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04410.x     Document Type: Article

References (41)

1. Martin P, Friedman LS. Chronic viral hepatitis and the management of chronic renal failure. Kidney Int 1995 47 : 1231 1241.
2. Centers for Disease Control. Recommendations for preventing transmission of infection among chronic haemodialysis patients. MMWR Recomm Rep 2001 50 : 1 43.
3. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005 18 : 52 61.
4. Igaki N, Nakaji M, Moriguchi R, et al. An outbreak of fulminant hepatitis in immunocompromised hemodialysis patients. J Gastroenterol 2003 38 : 968 976.
5. Burdick RA, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2002 63 : 2222 2229.
6. Rangel M, Coronado V, Euler G, Strikas R, for the Advisory Committee on Immunization Practices and the American Academy of Pediatrics. Vaccine recommendations for patients on chronic dialysis. Semin Dial 2002 13 : 101 107.
7. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: The effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther 2004 20 : 1053 1062.
8. Stevens CE, Alter HJ, Taylor PE, et al. Hepatitis B vaccine in patients receiving hemodialysis. N Engl J Med 1984 311 : 496 501.
9. Vagelli G, Calabrese G, Mazzotta A, Pratesi G, Gonella M. More about response to hepatitis B vaccine in hemodialysis patients. Nephron 1988 49 : 171.
10. Fernandez E, Betru MA, Gomez R, Montoliu J. Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephrol Dial Transplant 1996 11 : 1559 1563.
11. Navarro JF, Teruel JL, Mateos ML, Marcen R, Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol 1996 16 : 95 7.
12. Ahuja TS, Kumar S, Manosury H, Rodriguez H, Kuo YF. Hepatitis B vaccination in human immunodeficiency virus-infected adults receiving hemodialysis. Kidney Int 2005 67 : 1136 1141.
13. Sennesael JJ, van der Niepen P, Verbeelen DL. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 1991 40 : 121 128.
14. Pol S, Legendre C, Mattlinger B, Berthelot P, Krein H. Genetic basis of nonresponse to hepatitis B vaccine in hemodialysis patients. J Hepatol 1990 11 : 385 387.
15. Jibani MM, Heptonstall J, Walker AM, Bloodworth LO, Howard AJ. Hepatitis B immunization in UK renal units: failure to put policy into practice. Nephrol Dial Transplant 1994 9 : 1765 1768.
16. Fabrizi F, Di Filippo S, Marcelli D, et al. Recombinant hepatitis B vaccine use in chronic hemodialysis patients: long-term evaluation and cost-effectiveness analysis. Nephron 1996 72 : 536 543.
17. Ono K, Kahiwagi S. Complete seroconversion by low-dose intradermal injection of recombinant hepatitis B vaccine in hemodialysis patients. Nephron 1991 58 : 47 51.
18. DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003 42 : 1184 1192.
19. Poynard T, Conn HO. The retrieval of randomised clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. Control Clin Trials 1985 6 : 271 279.
20. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 7 : 177 188.
21. Petitti DB. Approaches to heterogeneity in meta-analysis. Statist Med 2001 20 : 3625 3633.
22. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistencies in meta-analysis. Br Med J 2003 327 : 557 560.
23. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988 7 : 889 894.
24. Klein S, Simes J, Blackburn GL. Total parenteral nutrition and cancer clinical trial. Cancer 1986 58 : 1378 1386.
25. Ayli MD, Ensari C, Ayli M, Mandiroglu F, Mut S. Effect of oral levamisole supplementation to hepatitis B vaccination on the rate of immune response in chronic hemodialysis patients. Nephron 2000 84 : 291 292.
26. Kayatas M. Levamisole treatment enhances protective antibody response to hepatitis B vaccination in hemodialysis patients. Artif Org 2002 26 : 492 496.
27. Argani H, Akhtarishojaie BE. Levamisole enhances immune responsiveness to intradermal and intramuscular hepatitis B vaccination in chronic hemodialysis patients. J Immune Based Ther Vaccines 2006 4 : 3.
28. Sali S, Alavian SM, Hajarizadeh B. Effect of levamisole supplementation on hepatitis B virus vaccination response in hemodialysis patients. Nephrology 2008 13 : 376 379.
29. Fabrizi F, Dixit V, Martin P. Meta-analysis: the adjuvant role of thymopentin on immunological response to hepatitis B virus vaccine in end-stage renal disease. Aliment Pharmacol Ther 2006 23 : 1559 1566.
30. Fabrizi F, Ganeshan SV, Dixit V, Martin P. Meta-analysis: The adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease. Aliment Pharmacol Ther 2006 24 : 789 796.
31. Miquilena-Colina ME, Lozano-Rodriguez T, Garcia-Pozo L, et al. Recombinant interferon-alpha2b improves immune response to hepatitis B vaccination in haemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. Vaccine 2009 54 : 5654 5660.
32. Tong NK, Beran J, Kee SA, et al. Immunogenicity and safety of an adjuvant hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005 68 : 2298 2303. (Pubitemid 43117807)
33. Surquin M, Tielemans CL, Kulcsar I, et al. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02-adjuvanted hepatitis B vaccine. Kidney Int 2010 77 : 247 255.
34. Janik J, Kopp WC, Smith JW, et al. Dose-related immunologic effects of levamisole in patients with cancer. J Clin Oncol 1993 11 : 125 135.
35. Modai D, Weissgarten J, Zolf R, et al. Effect of levamisole on chemotaxis of granulocytes from uremic patients. Nephron 1998 49 : 237 239.
36. Munoz A, Garcia RA, Perez-Aranda A. Potentiation by levamisole, methisoprinol, and adenine or adenosine of the inhibitory activity of human interferon against encephalomyocarditis virus. Antimicrob Agents Chemother 1986 30 : 192 195.
37. Wu T, Li Y, Bian Z, Liu G, Moher D. Randomized trials published in some Chinese journals: how many are randomised? Trials 2009 10 : 46.
38. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998 352 : 609 613. (Pubitemid 28380142)
39. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001 285 : 1987 1991. (Pubitemid 32366951)
40. Khan KS, Daya S, Jadad A. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 1996 156 : 661 666.
41. Miller ER, Alter MJ, Tokars JL. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis 1999 33 : 356 360.